Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study

Huang, Zhihui; Chen, Yanying; Pan, Liqin; Feng, Huijuan; Wu, Jing; Chen, Pan; Wang, Jing; Ouyang, Wei

doi:10.1016/j.ultrasmedbio.2021.05.013

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioactive iodine induced sialadenitis (RAIS) is an inflammatory lesion of the salivary gland( 20 ) that was first reported by Rigler and Scanlon ( 21 ), and was recently included in a new classification of clinical stomatology ( 22 ). Radioactive iodine induced sialadenitis have distinct imaging features in various imaging examinations ( 23 – 24 ). However, dynamic salivary gland scintigraphy is the first choice for follow-up of salivary glands after radioiodine treatment because it is functional imaging and is very sensitive to functional changes ( 19 , 25 , 26 ).…”

Section: Discussionmentioning

confidence: 99%

Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching

2022

View full text Add to dashboard Cite

ObjectivesThis study aimed to investigate the protection of the salivary glands by vitamin C administration at 2 and 24 h after an initial treatment using iodine-131 (131I) in patients with differentiated thyroid cancer (DTC) and examined the optimal administration time of vitamin C to protect the salivary glands from radiation injury.MethodThe clinical data of patients with differentiated thyroid carcinoma who had been treated with 131I in the Department of Nuclear Medicine in Shanxi Bethune Hospital from January 2014 to December 2020 were retrospectively analyzed. The propensity score matching method was adopted to match patients who received the administration of vitamin C at 2 h with those receiving administration at 24 h. A total of 230 pairs/460 patients were enrolled in the study. The chi-squared (χ2) or Fisher's exact test was used to compare the indicators representing the incidence of salivary gland injury between the two groups.ResultsThe incidence of salivary gland injury (17.39%) with acidic substances at 2 h was lower compared with administration at 24 h (26.96%). The incidence of acute salivary gland injury (15.22%) and chronic salivary gland injury (26.09%) in the 24-h group were higher than those in the 2-h group (4.78% and 18.26%, respectively). The differences in the left submandibular gland concentrate index and right submandibular gland concentrate index were statistically significant before and after treatment in both the 2 and the 24-h groups; these functions had been impaired after treatment.ConclusionsFollowing treatment with 131I, the protective effect of acidic substances administered at 2 and 24 h on the salivary glands were different. The incidence of salivary gland injury in the 2 h acid stimulation group was lower than in the 24 h acid stimulation group. The present study revealed that 131I treatment did cause some injury to the salivary glands and that the protective effect of administering vitamin C at 2 and 24 h may be limited. Accordingly, protection against salivary gland injury should be conducted using comprehensive measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching

2022

View full text Add to dashboard Cite

show abstract

“…Huang et al’s study including 446 patients with thyroid carcinoma, reported that the side effect of radioactive iodine on salivary glands occurs after a few months [ 40 ]. Also, Lee et al’s study, which investigated the effect of selenium intake on reducing the side effects of radioactive iodine on salivary glands, examined the findings after 6 months [ 38 ].…”

Section: Interventionsmentioning

confidence: 99%

The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial

Amini,

Golshani,

Moslehi

et al. 2023

Trials

View full text Add to dashboard Cite

Background Thyroid cancer is a very damaging disease. The most common treatment for this disease includes thyroidectomy and then using radioactive iodine (RAI). RAI has many side effects, including a decrease in salivary secretions, followed by dry mouth and oral and dental injuries, as well as increased inflammation and oxidative stress. Selenium can be effective in these patients by improving inflammation and oxidative stress and by modulating salivary secretions. So far, only one clinical trial has investigated the effect of selenium on thyroid cancer patients treated with radioiodine therapy (RIT) conducted on 16 patients; considering the importance of this issue, to show the potential efficacy of selenium in these patients, more high-quality trials with a larger sample size are warranted. Methods This is a parallel double-blind randomized controlled clinical trial that includes 60 patients aged 20 to 65 years with papillary thyroid cancer (PTC) treated with RAI and will be conducted in Seyyed al-Shohada Center, an academic center for referral of patients to receive iodine, Isfahan, Iran. Thirty patients will receive 200 µg of selenium for 10 days (3 days before to 6 days after RAI treatment) and another 30 patients will receive a placebo for the same period. Sonographic findings of major salivary glands, salivary secretions, and sense of taste will be evaluated before and 6 months after 10-day supplementation. Discussion Due to its anti-inflammatory and antioxidant effects, as well as improving salivary secretions, selenium may improve the symptoms of thyroid cancer treated with radioactive iodine. In past studies, selenium consumption has not reduced the therapeutic effects of radiation therapy, and at a dose of 300 to 500 μg/day, it has not had any significant side effects in many types of cancer under radiation therapy. Trial registration Iranian Registry of Clinical Trials IRCT20201129049534N6. Registered on 16 September 2021.

show abstract

Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study

Cited by 2 publications

References 27 publications

Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching

Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching

The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial

Contact Info

Product

Resources

About